225Ac- Prostate-specific membrane antigen (PSMA)-617 is a highly promising novel compound for therapy of prostate cancer. A remarkable therapeutic efficacy has been demonstrated in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients, with xerostomia as the main side effect. A promising strategy for minimization of side effects is based on optimization of the dosing regime while maintaining sufficient therapeutic efficacy for several cohorts of patients, including chemotherapy-naïve patients.
SATHEKGE Mike;
BRUCHERTSEIFER Frank;
KNOESEN Otto;
REYNEKE F;
LENGANA T;
LAWAL I;
BOSHOMANE T;
MOKOALA K;
VORSTER Mariza;
MORGENSTERN Alfred;
2019-07-24
ELSEVIER BV
JRC116489
1939-8654 (online),
https://publications.jrc.ec.europa.eu/repository/handle/JRC116489,
10.1016/j.jmir.2019.03.091 (online),
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Additional supporting files
| File name | Description | File type | |
|---|
